Medscape June 20, 2024
Kathleen Doheny

“My weight has always been kind of an issue,” said Gerald Fernandez, a 33-year-old mortgage broker in Naples, Florida. Over the years, he has sought advice from his physicians but felt unsatisfied with the guidance he has received: “They never gave me a solution, besides ‘Work out more, eat less.'”

Earlier this year, Fernandez found a new clinician who suggested he take a glucagon-like peptide 1 (GLP-1) receptor agonist for weight loss. He said he has lost about 20 lb in the 3 months he has been taking compounded semaglutide. But the medication is not the only difference-maker this time.

When Fernandez’s doctor, Yanet Diaz-Martell, MD, an internist and hospitalist at Physicians Regional Healthcare System in Naples, Florida, discussed his...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Physician, Provider
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
FDA approves 1st RSV vaccine for adults under 60
Lawmakers seek answers on Pfizer, Lilly telehealth moves
Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs?
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

Share This Article